(Q47327910)

14 January 2018

title

Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project (English)

1 reference

14 January 2018

main subject

coronary artery disease

1 reference

6

Jean Dallongeville

1 reference

14 January 2018

5

Guy De Backer

1 reference

14 January 2018

8

Andrzej Pajak

1 reference

14 January 2018

Kornelia Kotseva

2

object named as

Kornelia Kotseva

1 reference

14 January 2018

Dirk De Bacquer

3

object named as

Dirk De Bacquer

1 reference

14 January 2018

author name string

Delphine De Smedt

1

1 reference

14 January 2018

David Wood

4

1 reference

14 January 2018

Lehto Seppo

7

1 reference

14 January 2018

Zeljko Reiner

9

1 reference

14 January 2018

Diego Vanuzzo

10

1 reference

14 January 2018

Borislav Georgiev

11

1 reference

14 January 2018

Nina Gotcheva

12

1 reference

14 January 2018

Lieven Annemans

13

1 reference

14 January 2018

publication date

26 July 2012

1 reference

14 January 2018

published in

European Heart Journal

1 reference

14 January 2018

volume

33

1 reference

14 January 2018

issue

22

1 reference

14 January 2018

page(s)

2865-2872

1 reference

14 January 2018

Economic burden of cardiovascular diseases in the enlarged European Union

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

A systematic review and meta-analysis on the therapeutic equivalence of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Statins for secondary prevention of cardiovascular disease: the right dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Late relapse/sustained abstinence among former smokers: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

The dynamics of mortality in follow-up time after an acute myocardial infarction, lower extremity arterial disease and ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Probability of stroke: a risk profile from the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS210

Smoking cessation for the secondary prevention of coronary heart disease.

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD003041

30 December 2023

Identifiers

DOI

10.1093/EURHEARTJ/EHS210

1 reference

14 January 2018

PubMed ID

22843446

1 reference

14 January 2018